• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Selective Inhibitors of Nuclear Export (SINE) Induce p53, p21, FOXO,and IkB and Kill Malignant Cells

Selective Inhibitors of Nuclear Export (SINE) Induce p53, p21, FOXO,and IkB and Kill Malignant Cells

来源 :2011第四届世界癌症大会 | 被引量 : 0次 | 上传用户：a351200
【摘 要】
：
In order to maintain their malignant phenotype, neoplastic cells must neutralize most of their tumor suppressor (TSP) and growth regulatory (GRP) proteins.CRM1, also called exportin 1 (XPO1), is a key
【作 者】
：
Sharon Shacham 
【机 构】
：
Karyopharm Therapeutics Inc.USA
【出 处】
：
2011第四届世界癌症大会
【发表日期】
：
2011年3期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　In order to maintain their malignant phenotype, neoplastic cells must neutralize most of their tumor suppressor (TSP) and growth regulatory (GRP) proteins.CRM1, also called exportin 1 (XPO1), is a key nuclear export protein which controls the location of multiple tumor suppressor (TSP) and growth regulatory (GRP) pathways including p53, PI3K/AKT/FOXO, Wnt/β-catenin/APC and NF-kB/IkB.Inappropriate cytoplasmic localization can abrogate TSP/GRP functions and render chemotherapies ineffective.
其他文献
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum R
The major obstacle in platinum chemotherapy is the repair of platinum-damaged DNA that results in increased resistance, reduced apoptosis and, finally, treatment failure.Our research goal is to determ
会议
The Mass-action Law Based Algorithms and Computer Simulation for Econo-green Bio-research and Drug D
Drug discovery and drug development are facing a sustainability crises.The conventional basic biomedical research at molecular and cellular level is for knowledge accumulation that can be rarely trans
会议
Patient-derived Human Primary Tumor Model: A Good Predictive Preclinical Model to Evaluate Drug Effi
One of the greatest challenges faced by developers of new drugs and treatment strategies for cancer is the obvious need to test them in preclinical in vivo models that have a good probability of being
会议
NO-aspirin Induces Cell Death in Acute Lymphoblastic Leukemia through TNF-RI and Caspase-10 in a Lig
Although patients with acute lymphoblastic leukemia (ALL) usually achieve complete remission, disease relapse is common and difficult to treat, necessitating new strategies for the treatment of ALL.NO
会议
Fragments of Tumor Liberated Protein from Lung Cancer to Stimulate Immune Response to Attack Existin
TLP is a tumor-associated antigen and a 1 O0 kDa protein overexpressed in lung tumors and other epithelial adenocarcinomas.It is immunogenic in humans as shown by serum antibodies.Since TLP is a fragm
会议
The Role of Antibody Therapeutics in Today's Pharmaceutical Industry
Antibodies and Antibody contructs have developed to one of the most important biological therapeutics for the pharmaceutical industry.This holds especially true for the oncology sector.This review pre
会议
Targeting Her-2/neu Antigen to B Cells via CD19 Molecule: A Novel Vaccine for Breast Cancer Immunoth
Herceptin has been proven to be effective in the immunotherapy for Her-2/neu+ breast cancer.However, this adoptively transferred therapeutic Ab must be continuously given to the patient with huge fina
会议
A Sphingosine 1-phosphate Antibody-based Strategy Inhibits Intratumoral Hypoxia and Sensitizes to Ch
Background: Hypoxia promotes neovascularization, metastasis, growth and resistance to treatments.The activation of HIF-lα has been identified as the master mechanism of adaptation to hypoxia.We recent
会议
Mitochondrial Targeting Improves the Efficacy of Respiratory Chainspecific Anti-cancer Compounds
The number of patients diagnosed with neoplastic disease is expected to increase up to three-fold by 2030.Thus, the search for efficient and selective anti-cancer compounds with few side-effects is of
会议
Analysis of Drug Sensitivity-Resistance Transition in the PI3K/PTEN/AKT Signalling Network to HER2 I
A systems biology approach was developed to study in detail the effect of HER2 inhibitors (trastuzumab, pcrtuzumab) on the response of the ERK/PI3K/PTEN/AKT signalling network, one of dominant signall
会议